Society guideline links: Waldenström macroglobulinemia

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Monoclonal gammopathy of undetermined significance".)

International

●Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia (2020)

●International Workshops on Waldenström Macroglobulinaemia (IWWM): Consensus panel recommendations for the investigation and management of IgM and Waldenström-associated peripheral neuropathies (2017)

Europe

●European Myeloma Network (EMN): Recommendations on diagnosis and management of patients with rare plasma cell dyscrasias (2018)

●European Society for Medical Oncology (ESMO): Clinical practice guidelines for diagnosis, treatment and follow-up of Waldenström's macroglobulinaemia (2018)

United Kingdom

●British Society for Haematology (BSH): Guidelines on the diagnosis and management of Waldenström macroglobulinaemia (2022)

Australia-New Zealand

●Medical Scientific Advisory Group to the Myeloma Foundation of Australia (MSAG MFA): Clinical practice guidelines for the treatment of patients with Waldenström macroglobulinaemia (2017)

●MSAG MFA: Clinical practice guideline on Waldenström macroglobulinaemia (2016)

Japan

●[In Japanese] Japanese Society of Hematology (JSH): Clinical practice guidelines for hematological malignancies, 2nd edition (2020)